CIK 0001668243
- Non-accelerated filer
- Smaller reporting company
UroGen Pharma Ltd.
Sign in to watch- Ticker
- URGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 97707601
- Business address
- 9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
- 4 Open-market sale Chief Medical Officer sold 89 shares at $19.63 ($1,747)
- 4 Exercise or conversion Director acquired 3,241 shares (option exercise)
- 4 Exercise or conversion Director acquired 1,030 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 1,076 shares at $22.07 ($23,747)
- 4 Open-market sale Chief Medical Officer sold 100 shares at $22.12 ($2,212)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $18.50 ($185,000)
- 4 Open-market sale Chief Medical Officer sold 662 shares at $19.85 ($13,141)
- 4 Exercise or conversion Chief Executive Officer acquired 61,652 shares (option exercise)
- 4 Open-market sale Chief Medical Officer sold 101 shares at $20.95 ($2,116)
- 4 Open-market sale Chief Financial Officer sold 2,400 shares at an average $21.77 ($52,248)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Medical Officer sold 348 shares at $20.20 ($7,030)
- 4 Open-market sale Chief Financial Officer sold 509 shares at $22.82 ($11,615)
Page 8 of 12 · 233 filings